My main clinical research interest involve the efficacy and safety of anti-tumor necrosis factor (TNF) therapy in inflammatory bowel disease (IBD) and the role of therapeutic drug monitoring (TDM) of anti-TNF therapy in IBD. After finishing my MD, PhD from the Medical School, University of Athens, Greece, I jointed Evaggelismos Hospital, a large, tertiary IBD referral center, to start my GI Fellowship. There, I had the opportunity to participate in many investigator-initiated studies and pharmaceutical clinical trials. After completing my GI fellowship, I was then accepted as a post-doctoral research fellow in KULeuven, Belgium, a Center of Excellence and one of the best centers in IBD worldwide, having obtained two Fellowship Grants, one from the Hellenic Society of Gastroenterology and the other from the European Crohn’s and Colitis Organization. This led to several first author publications in high-impact medical journals, oral and poster presentations in big Medical Gastroenterology Congresses as well as awards and honors. Following a 3-year post-doctoral fellowship in Leuven, I then jointed the IBD Center at Beth Israel Deaconess Medical Center, Harvard Medical School, to continue my post-doctoral studies on the role of TDM of anti-TNF therapy in IBD. Based on my skills and expertise I have served as a reviewer for numerous medical journals and as an external evaluator for the European Commission Horizon 2020 programme.